Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kaletra (lopinavir/ritonavir).

Amanda H Corbett1, Michael L Lim, Angela D M Kashuba

  • 1School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA.

The Annals of Pharmacotherapy
|June 28, 2002
PubMed
Summary

Lopinavir/ritonavir is an effective HIV-1 protease inhibitor combination, enhancing drug exposure and suppressing viral load. It offers advantages in pharmacokinetics, efficacy, and resistance for treating HIV-1 infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing the Sensitivity of Mass Spectrometry Imaging through Spatial Signal Averaging.

Journal of the American Society for Mass Spectrometry·2026
Same author

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4<sup>+</sup> lymphocytes.

British journal of clinical pharmacology·2026
Same author

Exploring the Implementation of Community Pharmacist-Initiated Human Immunodeficiency Virus Post-Exposure Prophylaxis: A Cross-Sectional Survey Study.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention.

The Journal of infectious diseases·2026
Same author

Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application.

The Journal of antimicrobial chemotherapy·2025

Area of Science:

  • Pharmacology and Virology
  • Clinical Medicine

Background:

  • Lopinavir, a protease inhibitor (PI), has low systemic concentrations alone.
  • Ritonavir inhibits CYP3A4, boosting lopinavir exposure.

Purpose of the Study:

  • To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of lopinavir/ritonavir.

Main Methods:

  • Searched MEDLINE and AIDSline (1966-July 2001) for lopinavir, ABT-378, and Kaletra.
  • Reviewed publications, meeting abstracts, and unpublished data, including in vitro, preclinical, and clinical trials.

Main Results:

  • Lopinavir/ritonavir combination effectively suppresses HIV-1 RNA and increases CD4+ T cells.
  • Achieves lopinavir concentrations exceeding in vitro inhibitory levels for wild-type and resistant HIV.
  • May offer advantages over other PIs in pharmacokinetics, efficacy, and resistance profiles.

Conclusions:

  • Lopinavir/ritonavir is an effective treatment option for HIV-1-infected individuals.
  • Suitable for initial or salvage therapy in combination with other antiretrovirals.

Related Experiment Videos